Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks
Journal of Antimicrobial Chemotherapy · 03.09.2025 · 80 (9) · 2375-2383
DOI: 10.1093/jac/dkaf212 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 29.07.2025. Verfasst von Parul Patel und 11 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, NC, USA. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Hypertension, HIV Infections, Blood Pressure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
Background
To date, there are limited published data from randomized trials evaluating the effects of integrase strand transfer inhibitor-based regimens, including dolutegravir-based antiretroviral therapy (ART), on blood pressure (BP) in people with HIV-1 (PWH).
Objectives
This analysis evaluated BP changes from baseline and incident hypertension among ART-naive PWH randomized to dolutegravir-based three-drug ART or alternative comparator ART (cART) across pooled Phase 2/3 studies.
Methods
In this post hoc analysis of Phase 2/3 SPRING-1, SPRING-2, SINGLE and FLAMINGO clinical trials, BP was assessed at baseline, Week (W) 48 and W96. In PWH without evidence of hypertension at baseline, incident hypertension was defined as a single systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg measured after a 5 min rest, a hypertension adverse event and/or antihypertensive medication use during follow-up. Baseline factors associated with incident hypertension at W96 were assessed through multivariate analyses. BP changes between dolutegravir and cART were also assessed.
Results
Among 2345 randomized participants, 1815 (77%) had no evidence of hypertension at baseline; 927 received dolutegravir-based ART and 888 received cART. Through W96, incident hypertension did not differ between groups [dolutegravir, 23% (n = 180/779); cART, 21% (n = 139/665); adjusted OR, 1.02; 95% CI, 0.79–1.33]; ∼1% of participants initiated antihypertensive medication through W96 (dolutegravir, n = 3; cART, n = 1). At W96, no significant BP changes from baseline were observed (systolic BP, P = 0.741; diastolic BP, P = 0.683).
Conclusions
Relative to non-dolutegravir-containing cART, dolutegravir-containing three-drug ART did not show any impact on incident hypertension in ART-naive PWH without evidence of hypertension at baseline through W96.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ViiV Healthcare, Durham, NC, USA.
- ViiV Healthcare, Brentford, UK.
- GSK, Brentford, UK.
- Hospital Clínic de Barcelona and University of Barcelona, Barcelona, Spain.
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- GSK, Mississauga, ON, Canada.
ORCID-Profile: Esteban Martinez
Förderung
- ViiV Healthcare
Zitieren
APA
Patel, P., Milinkovic, A., Grove, R., Govan, L., McKenna, M., Wynne, B., Henegar, C., Martinez, E., Dimondi, P., Chow, K., Payvandi, N., & Jones, B. (2025). Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks. Journal of Antimicrobial Chemotherapy, 80(9), 2375-2383. https://doi.org/10.1093/jac/dkaf212
Vancouver
Patel P, Milinkovic A, Grove R, Govan L, McKenna M, Wynne B, et al. Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks. Journal of Antimicrobial Chemotherapy. 2025;80(9):2375-2383. doi:10.1093/jac/dkaf212
BibTeX
@article{Patel2025,
author = {Patel, Parul and Milinkovic, Ana and Grove, Richard and Govan, Lindsay and McKenna, Michael and Wynne, Brian and Henegar, Cassidy and Martinez, Esteban and Dimondi, Paul and Chow, Ken and Payvandi, Nassrin and Jones, Bryn},
title = {Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {9},
pages = {2375--2383},
doi = {10.1093/jac/dkaf212}
}
EUVIMED